TROY HANSON: Open Payments
NPI 1215471065 · REXBURG, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$361 in 23 payments from 8 companies in 2025. Trend: 2023 $88 · 2024 $133 · 2025 $361
Food & beverage: $361
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $207 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $45 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Novartis Pharmaceuticals Corporation | 1 | $15 |
| Corium, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 2 | $12 |
Products named: QULIPTA, VRAYLAR, CAPLYTA, Auvelity, UBRELVY, FANAPT, COSENTYX, Azstarys.
Industry payments across ID — which companies pay providers there.
